FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2137404654> ?p ?o ?g. }

• W2137404654 endingPage "797" @default.
• W2137404654 startingPage "788" @default.
• W2137404654 abstract "Summary Background Omalizumab (Xolair ® ) is a recombinant humanized monoclonal anti‐IgE antibody with proven efficacy in patients with moderate‐to‐severe and severe persistent allergic (IgE‐mediated) asthma. Objective To review clinical study data to assess the safety profile of omalizumab. Methods We analysed the safety of omalizumab using data from completed clinical studies (up to 1 year) involving more than 7500 patients with asthma, rhinitis or related conditions and up to 4 years in one study of patients with severe allergic asthma, as well as post‐marketing safety data. Analysis focuses on the risk of immune‐system effects, hypersensitivity reactions, malignant neoplasia, parasitic infections and thrombocytopenia. Results Omalizumab exhibited a good safety and tolerability profile that was maintained up to 4 years in one study. The incidence of anaphylaxis was 0.14% in omalizumab‐treated patients and 0.07% in control patients. No omalizumab‐treated patient developed measurable anti‐omalizumab antibodies. Post‐marketing, based on estimated exposure of 57 300 patients (June 2003–December 2006), the frequency of anaphylaxis attributed to omalizumab use was estimated to be at least 0.2% of patients. Current clinical trial data do not support an increased risk of malignant neoplasia or thrombocytopenia with omalizumab. Conclusion Data indicate that the proven efficacy of add‐on omalizumab in patients with moderate‐to‐severe or severe allergic asthma is accompanied by a favourable safety and tolerability profile." @default.
• W2137404654 created "2016-06-24" @default.
• W2137404654 creator A5013167015 @default.
• W2137404654 creator A5021417774 @default.
• W2137404654 creator A5027516170 @default.
• W2137404654 creator A5039635841 @default.
• W2137404654 creator A5069959810 @default.
• W2137404654 creator A5089020623 @default.
• W2137404654 date "2009-05-11" @default.
• W2137404654 modified "2023-10-17" @default.
• W2137404654 title "Safety and tolerability of omalizumab" @default.
• W2137404654 cites W1547456763 @default.
• W2137404654 cites W1779662836 @default.
• W2137404654 cites W1835232554 @default.
• W2137404654 cites W1893278748 @default.
• W2137404654 cites W1967215794 @default.
• W2137404654 cites W1984064916 @default.
• W2137404654 cites W1987444459 @default.
• W2137404654 cites W1995784152 @default.
• W2137404654 cites W1997872920 @default.
• W2137404654 cites W2002292213 @default.
• W2137404654 cites W2004147651 @default.
• W2137404654 cites W2010946738 @default.
• W2137404654 cites W2014574895 @default.
• W2137404654 cites W2022442006 @default.
• W2137404654 cites W2025265625 @default.
• W2137404654 cites W2050598338 @default.
• W2137404654 cites W2053591346 @default.
• W2137404654 cites W2055220989 @default.
• W2137404654 cites W2060441790 @default.
• W2137404654 cites W2060636831 @default.
• W2137404654 cites W2097981132 @default.
• W2137404654 cites W2098968578 @default.
• W2137404654 cites W2101439161 @default.
• W2137404654 cites W2105060822 @default.
• W2137404654 cites W2110052844 @default.
• W2137404654 cites W2148317660 @default.
• W2137404654 cites W2154777347 @default.
• W2137404654 cites W2156916462 @default.
• W2137404654 cites W2160953471 @default.
• W2137404654 cites W2162051917 @default.
• W2137404654 cites W3022148767 @default.
• W2137404654 doi "https://doi.org/10.1111/j.1365-2222.2009.03214.x" @default.
• W2137404654 hasPubMedId "https://pubmed.ncbi.nlm.nih.gov/19302249" @default.
• W2137404654 hasPublicationYear "2009" @default.
• W2137404654 type Work @default.
• W2137404654 sameAs 2137404654 @default.
• W2137404654 citedByCount "209" @default.
• W2137404654 countsByYear W21374046542012 @default.
• W2137404654 countsByYear W21374046542013 @default.
• W2137404654 countsByYear W21374046542014 @default.
• W2137404654 countsByYear W21374046542015 @default.
• W2137404654 countsByYear W21374046542016 @default.
• W2137404654 countsByYear W21374046542017 @default.
• W2137404654 countsByYear W21374046542018 @default.
• W2137404654 countsByYear W21374046542019 @default.
• W2137404654 countsByYear W21374046542020 @default.
• W2137404654 countsByYear W21374046542021 @default.
• W2137404654 countsByYear W21374046542022 @default.
• W2137404654 countsByYear W21374046542023 @default.
• W2137404654 crossrefType "journal-article" @default.
• W2137404654 hasAuthorship W2137404654A5013167015 @default.
• W2137404654 hasAuthorship W2137404654A5021417774 @default.
• W2137404654 hasAuthorship W2137404654A5027516170 @default.
• W2137404654 hasAuthorship W2137404654A5039635841 @default.
• W2137404654 hasAuthorship W2137404654A5069959810 @default.
• W2137404654 hasAuthorship W2137404654A5089020623 @default.
• W2137404654 hasConcept C120665830 @default.
• W2137404654 hasConcept C121332964 @default.
• W2137404654 hasConcept C126322002 @default.
• W2137404654 hasConcept C141105273 @default.
• W2137404654 hasConcept C159654299 @default.
• W2137404654 hasConcept C16005928 @default.
• W2137404654 hasConcept C197934379 @default.
• W2137404654 hasConcept C203014093 @default.
• W2137404654 hasConcept C207480886 @default.
• W2137404654 hasConcept C2775933838 @default.
• W2137404654 hasConcept C2776042228 @default.
• W2137404654 hasConcept C2778375690 @default.
• W2137404654 hasConcept C2778564945 @default.
• W2137404654 hasConcept C535046627 @default.
• W2137404654 hasConcept C61511704 @default.
• W2137404654 hasConcept C71924100 @default.
• W2137404654 hasConceptScore W2137404654C120665830 @default.
• W2137404654 hasConceptScore W2137404654C121332964 @default.
• W2137404654 hasConceptScore W2137404654C126322002 @default.
• W2137404654 hasConceptScore W2137404654C141105273 @default.
• W2137404654 hasConceptScore W2137404654C159654299 @default.
• W2137404654 hasConceptScore W2137404654C16005928 @default.
• W2137404654 hasConceptScore W2137404654C197934379 @default.
• W2137404654 hasConceptScore W2137404654C203014093 @default.
• W2137404654 hasConceptScore W2137404654C207480886 @default.
• W2137404654 hasConceptScore W2137404654C2775933838 @default.
• W2137404654 hasConceptScore W2137404654C2776042228 @default.
• W2137404654 hasConceptScore W2137404654C2778375690 @default.
• W2137404654 hasConceptScore W2137404654C2778564945 @default.
• W2137404654 hasConceptScore W2137404654C535046627 @default.
• W2137404654 hasConceptScore W2137404654C61511704 @default.

• next